Form 4: BioCryst Pharmaceuticals Director Alan G. Levin Reports Stock and Option Grants

Director Alan G. Levin reports the acquisition of restricted stock units and stock options in BioCryst Pharmaceuticals as part of a non-employee director compensation policy.

Summary

• Alan G. Levin, a director at BioCryst Pharmaceuticals, reported a transaction on June 12, 2024.
• The transaction involved the acquisition of 6,820 shares of common stock at $0 and 49,933 stock options with an exercise price of $6.30.
• These acquisitions were part of an automatic non-employee director grant under the company's compensation policy.
• The restricted stock units will vest on the first anniversary of the grant date.
• The stock options are exercisable from June 12, 2025, and expire on June 12, 2034.
• Following the reported transaction, Levin beneficially owns 51,771 shares of common stock and 49,933 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects standard director compensation practices, indicating stable corporate governance. The grants align director interests with shareholders, which is generally viewed positively.

Positives

• The grant of stock and options aligns the director's interests with those of the shareholders.
• The vesting schedule for the restricted stock units encourages long-term commitment from the director.

Industry Context

Director compensation through stock and option grants is a common practice in the pharmaceutical industry to incentivize performance and align management interests with shareholders.

Comparison to Industry Standards

• Stock option grants to non-employee directors are a standard practice across the pharmaceutical industry.
• Companies like Amgen and Gilead Sciences also utilize stock options and restricted stock units as part of their director compensation packages.
• The vesting schedules and exercise prices are generally aligned with industry norms to ensure long-term commitment and value creation.

Stakeholder Impact

• The stock and option grants align the director's interests with those of the shareholders, potentially leading to decisions that benefit shareholder value.
• The grants do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates